Mark Velleca, StrideBio CEO
April 5, 2023 10:53 AM EDTUpdated 02:04 PM
Deals
R&D

Gink­go snaps up gene ther­a­py vec­tor as­sets from Stride­Bio

Tyler Patchen

News Reporter

Gink­go Bioworks is pick­ing up some vi­ral vec­tors, part of what it calls an on­go­ing push in­to gene ther­a­py ser­vices.

On Wednes­day, Gink­go an­nounced that …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

A service from the Financial Times